ArticleACS synthetic biology2025
Bioluminescence-Driven Optimization of Geminivirus-Based Vectors as Tools for Plant Biotechnology.
Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioluminescent sentinel plants enable autonomous diagnostics of viral infections.Nature communications · 2026Article
- Efficient production of functional cholera toxin B subunit using geminiviral replicons inFrontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral replicons are valuable tools in plant biotechnology, widely utilized to increase recombinant protein production. Their ability to amplify gene dosage in a trigger-dependent manner also opens doors to regulatory applications. This work focuses on optimizing geminivirus-based vectors for Synthetic Biology applications in plants, using autobioluminescence as a sensitive, real-time reporter to characterize gene expression. Specifically, geminivirus-based synthetic replicons derived from bean yellow dwarf virus (BeYDV), tomato yellow leaf curl virus (TYLCV), and beet curly top virus (BCTV) were engineered and assessed for basal expression, inducibility, and recombinant protein coexpression potential. Our study provided insights into the strengths and limitations of each geminiviral replicon. BeYDV replicon displayed a robust activation profile suitable for complex tasks such as multigene expression, while TYLCV showed high expression levels despite moderate basal leakage. In contrast, BCTV demonstrated less favorable control and expression levels. Through a bioluminescence-based screening, the TYLCV system was further optimized to improve regulatory precision. These findings highlight the versatility of geminivirus replicons, paving the way for future engineering of synthetic gene circuits in plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.